Exiqon Reaffirms Plan to Pursue miRNA Dx Only Through Partnerships, Provides Few Details on Programs

The company also reported its financial results for 2009, posting a slight increase in its net loss for the year, which included the impact of operations from its now-discontinued Oncotech unit.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.